AI assistant
Sending…
Cartesian Therapeutics, Inc. — Director's Dealing 2021
Apr 2, 2021
33483_dirs_2021-04-01_8f8a5284-f428-428f-a443-373229fd8ec9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2021-03-30
Reporting Person: Myers Scott Dunseth (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-03-30 | Stock Option (Right to Buy) | $4.01 | A | 40000 | Acquired | 2031-03-29 | Common Stock (40000.0) | Direct |
Footnotes
F1: This option vests in full on March 30, 2022.
More from Cartesian Therapeutics, Inc.
Regulatory Filings
2026
May 26
Regulatory Filings
2026
Apr 30
Interim / Quarterly Report
2026
Apr 30
Regulatory Filings
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 28
Regulatory Filings
2026
Mar 30
Major Shareholding Notification
2026
Feb 5
Regulatory Filings
2026
Jan 9
Director's Dealing
2026
Jan 8
Director's Dealing
2026
Jan 8